By Cecilia Butini

 

Sanofi SA and AstraZeneca PLC said Monday that Sanofi would retain full commercial control on an antibody treatment for respiratory syncytial virus in the U.S. as part of a contractual agreement between the two companies and Swedish Orphan Biovitrum AB.

Under the new arrangements, Swedish Orphan Biovitrum, known as Sobi, will terminate its participation agreement with AstraZeneca and will enter into a direct royalty agreement with Sanofi to share a portion of U.S. net sales of the drug.

The drug, named nirsevimab, will still be jointly commercialized by Sanofi and AstraZeneca in territories outside the U.S., said Sanofi.

Sobi had said on April 9 that it would pay Sanofi $66 million as reimbursement for prior research-and-development costs for the treatment in the U.S., and that it would receive quarterly royalties on net U.S. sales of the drug from Sanofi. Royalty rates will start at 25% at launch in 2023, will continue in 2024 and will increase each year until 2028, reaching a range of 30% to 35% of net sales, said Sobi.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

April 11, 2023 02:39 ET (06:39 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Astrazeneca.